Eton Q3 product sales $22.5M (+129% YoY), non-GAAP EPS $0.04, ET-600 PDUFA Feb 2026

Eton Pharmaceuticals, Inc.

2025-Q3 EPS reported -$0.23 revenue$58,669,000

Product sales of $22.5M, up 129% YoY; 19th consecutive quarter of sequential growth.
GAAP EPS loss $0.07; non-GAAP diluted EPS $0.04; Adjusted EBITDA $2.9M.
ET-600 NDA accepted with PDUFA date February 25, 2026; launch production scheduled.
INCRELEX largest revenue contributor; GALZIN exceeded year-end target of 200 active patients.
Generated $12.0M cash from operations; ending cash balance $37.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.